Cargando…

Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells

The standard treatment for Triple Negative Breast Cancer (TNBC) patients is cytotoxic chemotherapy, but it is restricted since the duration of response is usually short. Blocking the PD-1/PD-L1 pathway through monoclonal antibodies (mAbs) appears to be a promising therapeutic strategy for TNBC patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Juliá, Estefanía Paula, Amante, Analía, Pampena, María Betina, Mordoh, José, Levy, Estrella Mariel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159755/ https://www.ncbi.nlm.nih.gov/pubmed/30294328 http://dx.doi.org/10.3389/fimmu.2018.02140

Ejemplares similares

Cetuximab and IL-15 Promote NK and Dendritic Cell Activation In Vitro in Triple Negative Breast Cancer
por: Juliá, Estefanía Paula, et al.
Publicado: (2020)

Natural Killer Cells as Helper Cells in Dendritic Cell Cancer Vaccines
por: Pampena, María Betina, et al.
Publicado: (2015)

Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15
por: Rocca, Yamila Sol, et al.
Publicado: (2016)

High neutrophil to lymphocyte ratio and decreased CD69(+)NK cells represent a phenotype of high risk in early-stage breast cancer patients
por: Mandó, Pablo, et al.
Publicado: (2018)

Biological role of NK cells and immunotherapeutic approaches in breast cancer
por: Roberti, María P., et al.
Publicado: (2012)

Early Events of the Reaction Elicited by CSF-470 Melanoma Vaccine Plus Adjuvants: An In Vitro Analysis of Immune Recruitment and Cytokine Release
por: Pampena, María B., et al.
Publicado: (2017)

Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report
por: Aris, Mariana, et al.
Publicado: (2018)

Natural Killer Cells in Human Cancer: From Biological Functions to Clinical Applications
por: Levy, Estrella Mariel, et al.
Publicado: (2011)

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
por: Donahue, Renee N., et al.
Publicado: (2017)

Editorial: “Cancer Immunotherapy: Lights and Shadows”
por: Barrio, María Marcela, et al.
Publicado: (2015)

Essential Role of NK Cells in IgG Therapy for Experimental Autoimmune Encephalomyelitis
por: Chong, Wai Po, et al.
Publicado: (2013)

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells
por: Lepone, Lauren, et al.
Publicado: (2015)

Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice
por: Roberti, María Paula, et al.
Publicado: (2012)

Host protective ASP-based vaccine against the parasitic nematode Ostertagia ostertagi triggers NK cell activation and mixed IgG1-IgG2 response
por: González-Hernández, Ana, et al.
Publicado: (2016)

The negative NK cell maturation checkpoint Foxo1
por: Deng, Youcai, et al.
Publicado: (2015)

Serum checkpoint molecules in patients with IgG4-related disease (IgG4-RD)
por: Matsumoto, Haruki, et al.
Publicado: (2021)

Subclasses of allergen-specific IgG: Serum IgG2 and IgG3 levels are not predicted by IgG1/IgG4 levels
por: MacGlashan, Donald, et al.
Publicado: (2021)

Impairment of IgG Fc functions promotes tumor progression and suppresses NK cell antitumor actions
por: Fan, Xuejun, et al.
Publicado: (2022)

Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants
por: Pampena, María B., et al.
Publicado: (2018)

Immunotherapy in Merkel cell carcinoma: role of Avelumab
por: Palla, Amruth R, et al.
Publicado: (2018)

Association of dengue infection with anti-alpha-gal antibodies, IgM, IgG, IgG1, and IgG2
por: Olajiga, Olayinka M., et al.
Publicado: (2022)

NK Cell Dysfunction and Checkpoint Immunotherapy
por: Bi, Jiacheng, et al.
Publicado: (2019)

High Dose Intravenous IgG Therapy Modulates Multiple NK Cell and T Cell Functions in Patients With Immune Dysregulation
por: McAlpine, Sarah M., et al.
Publicado: (2021)

Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette–Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study
por: Mordoh, José, et al.
Publicado: (2017)

Specificity of fc receptors for IgG2a, IgG1/IgG2b, and IgE on rat macrophages
Publicado: (1981)

Immunofluorescence Staining for IgG Subclass: Cause for Discrepancy in the Detection of IgG1
por: Kudose, Satoru, et al.
Publicado: (2023)

Syngeneic B16-F1 cells are more efficient than allogeneic Cloudman cells as antigen source in DC-based vaccination in the B16-F1 murine melanoma model
por: Keon, Soledad Mac, et al.
Publicado: (2019)

IgG1 memory B cells keep the memory of IgE responses
por: He, Jin-Shu, et al.
Publicado: (2017)

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
por: Bullement, Ash, et al.
Publicado: (2019)

Avelumab-induced Pneumonitis in Metastatic Merkel Cell Carcinoma
por: Morimoto, Toshiki, et al.
Publicado: (2022)

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
por: Hicks, Kristin C., et al.
Publicado: (2018)

Prognostic implication of IgG4 and IgG1-positive cell infiltration in the lung in patients with idiopathic interstitial pneumonia
por: Komatsu, Masamichi, et al.
Publicado: (2022)

Harnessing NK Cell Checkpoint-Modulating Immunotherapies
por: Chauhan, Sachin Kumar Singh, et al.
Publicado: (2020)

NK Cell-Based Immune Checkpoint Inhibition
por: Khan, Muhammad, et al.
Publicado: (2020)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
por: Pesce, Silvia, et al.
Publicado: (2019)

Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort
por: Levy, Sonja, et al.
Publicado: (2020)

Liposomes Bearing Non-Bilayer Phospholipid Arrangements Induce Specific IgG Anti-Lipid Antibodies by Activating NK1.1(+), CD4(+) T Cells in Mice
por: Landa-Saldívar, Carla, et al.
Publicado: (2022)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

Product review: avelumab, an anti-PD-L1 antibody
por: Collins, Julie M., et al.
Publicado: (2018)

Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid
por: Sadik, Christian D., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vsdv3glqp831obc4pt8urmsnaa